CN115960919A - 基于细菌的蛋白质递送 - Google Patents

基于细菌的蛋白质递送 Download PDF

Info

Publication number
CN115960919A
CN115960919A CN202211325325.8A CN202211325325A CN115960919A CN 115960919 A CN115960919 A CN 115960919A CN 202211325325 A CN202211325325 A CN 202211325325A CN 115960919 A CN115960919 A CN 115960919A
Authority
CN
China
Prior art keywords
protein
proteins
bacterial strain
negative bacterial
gram
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202211325325.8A
Other languages
English (en)
Chinese (zh)
Inventor
塞西尔·阿里厄梅卢
西蒙·伊泰格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Basel
Original Assignee
Universitaet Basel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Basel filed Critical Universitaet Basel
Publication of CN115960919A publication Critical patent/CN115960919A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/24—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/24—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • G01N2333/245—Escherichia (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/24—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • G01N2333/255—Salmonella (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202211325325.8A 2014-05-21 2015-05-20 基于细菌的蛋白质递送 Pending CN115960919A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP14169335 2014-05-21
EP14169335.8 2014-05-21
CN201580040391.2A CN107001431B (zh) 2014-05-21 2015-05-20 基于细菌的蛋白质递送
PCT/EP2015/061086 WO2015177197A1 (en) 2014-05-21 2015-05-20 Bacteria-based protein delivery

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580040391.2A Division CN107001431B (zh) 2014-05-21 2015-05-20 基于细菌的蛋白质递送

Publications (1)

Publication Number Publication Date
CN115960919A true CN115960919A (zh) 2023-04-14

Family

ID=50771120

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580040391.2A Active CN107001431B (zh) 2014-05-21 2015-05-20 基于细菌的蛋白质递送
CN202211325325.8A Pending CN115960919A (zh) 2014-05-21 2015-05-20 基于细菌的蛋白质递送

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201580040391.2A Active CN107001431B (zh) 2014-05-21 2015-05-20 基于细菌的蛋白质递送

Country Status (23)

Country Link
US (3) US10889823B2 (enExample)
EP (2) EP3145946B1 (enExample)
JP (3) JP6797025B2 (enExample)
KR (2) KR102440293B1 (enExample)
CN (2) CN107001431B (enExample)
AU (1) AU2015261905B2 (enExample)
BR (1) BR112016027196B1 (enExample)
CA (1) CA2948570C (enExample)
CY (1) CY1122701T1 (enExample)
DK (1) DK3145946T3 (enExample)
EA (1) EA201692025A1 (enExample)
ES (1) ES2754508T3 (enExample)
HR (1) HRP20192050T1 (enExample)
HU (1) HUE046025T2 (enExample)
IL (2) IL248827B (enExample)
LT (1) LT3145946T (enExample)
PL (1) PL3145946T3 (enExample)
PT (1) PT3145946T (enExample)
RS (1) RS59583B1 (enExample)
SG (1) SG11201609629YA (enExample)
SI (1) SI3145946T1 (enExample)
SM (1) SMT201900626T1 (enExample)
WO (1) WO2015177197A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201900626T1 (it) 2014-05-21 2020-01-14 Univ Basel Veicolazione di proteine basate su batteri
US12351805B2 (en) 2015-11-19 2025-07-08 Northeastern University Method of making recombinant silk and silk-amyloid hybrid proteins using bacteria
US11702663B2 (en) * 2015-11-19 2023-07-18 Universität Basel Bacteria-based protein delivery
LT3377094T (lt) 2015-11-19 2021-08-10 Universität Basel Susilpninto virulentiškumo bakterijos, skirtos piktybinių solidinių navikų gydymui
US11365225B2 (en) * 2015-11-19 2022-06-21 President And Fellows Of Harvard College Method of making recombinant silk and silk-amyloid hybrid proteins using bacteria
SI3559022T1 (sl) * 2016-12-20 2021-11-30 Universitaet Basel Dostava proteina na osnovi virulentno oslabljenih bakterij
WO2018183850A2 (en) * 2017-03-31 2018-10-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods, systems, and compositions for inhibiting virulance of a/e family pathogens
CN107858367A (zh) * 2017-12-05 2018-03-30 复旦大学附属肿瘤医院 一种利用细菌靶向投递治疗性蛋白的系统及其应用
BR112021021839A2 (pt) * 2019-05-01 2022-01-04 Innate Biologics Llc Composições imunomodulatórias e métodos
US20220362361A1 (en) * 2019-10-18 2022-11-17 University Of Virginia Patent Foundation Compositions and methods for producing enhanced immune responses and rapid antibody production
CN111848803B (zh) * 2020-07-21 2022-04-08 珠海中科先进技术研究院有限公司 一种具有突出酸碱稳定性的磷脂酰肌醇蛋白聚糖3的纳米抗体及其制备方法
CN114480463B (zh) * 2020-10-26 2024-07-16 南京吉芮康生物科技研究院有限公司 一种减毒沙门氏菌分泌表达rbd结构域蛋白的新型冠状病毒疫苗抗原递呈系统及其应用
CN114712496B (zh) * 2022-04-29 2023-10-13 中山大学·深圳 一种展示新抗原的细菌衍生外膜囊泡疫苗及制备方法和在制备癌症免疫治疗试剂盒中的应用
CN115896314A (zh) * 2022-07-14 2023-04-04 四川大学 一种基于lf-rpa的猕猴桃细菌性溃疡病菌的无设备、可视化检测方法
CN117511912B (zh) * 2023-12-22 2024-03-29 辉大(上海)生物科技有限公司 IscB多肽、包含其的系统及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965381A (en) * 1998-03-06 1999-10-12 Ludwig Institute For Cancer Research Delivery of proteins into eukaryotic cells with recombinant yersinia
WO2000002996A2 (en) * 1998-07-10 2000-01-20 Cornell Research Foundation, Inc. Recombinant constructs and systems for secretion of proteins via type iii secretion systems
WO2008019183A2 (en) * 2006-05-18 2008-02-14 The Regents Of The University Of California Biopolymer and protein production using type iii secretion systems of gram negative bacteria
US20080187520A1 (en) * 2003-11-13 2008-08-07 Universite Joseph Fourier Tool for the transfer and production of proteins using the pseudomonas type III secretion system

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020160502A1 (en) 2000-09-26 2002-10-31 Roger Williams Hospital Recombinant BCG vaccines for the prevention and treatment of cancer
US20040147719A1 (en) * 2001-03-26 2004-07-29 Guy Cornelis Type III bacterial strains for use in medicine
WO2007011106A1 (en) 2005-07-15 2007-01-25 M2Sys Co., Ltd An opening and closing apparatus for small image photographing devices
JP2009510169A (ja) 2005-10-04 2009-03-12 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 細菌抗原送達系を用いた免疫応答を刺激するための方法
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
EP1921149A1 (en) * 2006-11-13 2008-05-14 AEterna Zentaris GmbH Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof
AU2009226972B2 (en) 2008-03-17 2014-05-29 Gerhard Heusipp YopM as delivery vehicle for cargo molecules and as biological therapeutic for immunomodulation of inflammatory reactions
WO2010135563A1 (en) * 2009-05-22 2010-11-25 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium and methods of antigen and nucleic acid delivery
WO2015042706A1 (en) 2013-09-24 2015-04-02 Medicenna Therapeutics Pte Ltd Interleukin-4 receptor-binding fusion proteins and uses thereof
US10143743B2 (en) 2013-11-18 2018-12-04 Yale University Non-replicating bacterial nanoparticle delivery system and methods of use
SMT201900626T1 (it) 2014-05-21 2020-01-14 Univ Basel Veicolazione di proteine basate su batteri
LT3377094T (lt) 2015-11-19 2021-08-10 Universität Basel Susilpninto virulentiškumo bakterijos, skirtos piktybinių solidinių navikų gydymui
US11702663B2 (en) * 2015-11-19 2023-07-18 Universität Basel Bacteria-based protein delivery
SI3559022T1 (sl) 2016-12-20 2021-11-30 Universitaet Basel Dostava proteina na osnovi virulentno oslabljenih bakterij

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965381A (en) * 1998-03-06 1999-10-12 Ludwig Institute For Cancer Research Delivery of proteins into eukaryotic cells with recombinant yersinia
CN1304442A (zh) * 1998-03-06 2001-07-18 皮埃尔B·范·德·布鲁根 用重组耶尔森氏菌将蛋白质送递到真核生物细胞中
WO2000002996A2 (en) * 1998-07-10 2000-01-20 Cornell Research Foundation, Inc. Recombinant constructs and systems for secretion of proteins via type iii secretion systems
US20080187520A1 (en) * 2003-11-13 2008-08-07 Universite Joseph Fourier Tool for the transfer and production of proteins using the pseudomonas type III secretion system
WO2008019183A2 (en) * 2006-05-18 2008-02-14 The Regents Of The University Of California Biopolymer and protein production using type iii secretion systems of gram negative bacteria

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AHMED KAMAL等: "Apoptosis-inducing agents: a patent review", EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 24, no. 3, 10 January 2014 (2014-01-10), pages 339 - 354, XP055173440, DOI: 10.1517/13543776.2014.877445 *
LKJ STADLER等: "The use of a neutral peptide aptamer scaffold to anchor BH3 peptides constitutes a viable approach to studying their function", CELL DEATH AND DISEASE, vol. 5, 30 January 2014 (2014-01-30), pages 1 - 9, XP055315981, DOI: 10.1038/cddis.2013.564 *
PARTHO GHOSH等: "Process of Protein Transport by the Type III Secretion System", MICROBIOL MOL BIOL REV., vol. 68, no. 4, 31 December 2004 (2004-12-31), pages 771 - 795 *
Y. ZHANG等: "Type III Secretion System-Dependent Translocation of Ectopically Expressed Yop Effectors into Macrophages by Intracellular Yersinia pseudotuberculosis", INFECTION AND IMMUNITY, vol. 79, no. 11, 15 August 2011 (2011-08-15), pages 4322 - 4331, XP055204813, DOI: 10.1128/IAI.05396-11 *
杨倩: "病原菌入侵宿主细胞的机制研究进展", 免疫学杂志, vol. 26, no. 2, 28 February 2010 (2010-02-28), pages 171 - 174 *
王蔚淼等: "细菌Ⅲ型分泌系统的研究进展", 畜牧与兽医, vol. 38, no. 6, 31 December 2006 (2006-12-31), pages 58 - 60 *

Also Published As

Publication number Publication date
PL3145946T3 (pl) 2020-02-28
US20240401065A1 (en) 2024-12-05
US10889823B2 (en) 2021-01-12
AU2015261905B2 (en) 2020-07-09
SI3145946T1 (sl) 2019-12-31
CA2948570A1 (en) 2015-11-26
IL283280B1 (en) 2023-04-01
IL248827B (en) 2021-07-29
JP2022109967A (ja) 2022-07-28
US12091670B2 (en) 2024-09-17
SMT201900626T1 (it) 2020-01-14
HUE046025T2 (hu) 2020-01-28
WO2015177197A1 (en) 2015-11-26
CN107001431A (zh) 2017-08-01
EP3660034A1 (en) 2020-06-03
JP2017517257A (ja) 2017-06-29
BR112016027196B1 (pt) 2023-05-02
SG11201609629YA (en) 2016-12-29
EP3145946B1 (en) 2019-08-14
CA2948570C (en) 2023-09-12
EA201692025A1 (ru) 2017-05-31
US20170198297A1 (en) 2017-07-13
US20210155942A1 (en) 2021-05-27
JP6797025B2 (ja) 2020-12-09
DK3145946T3 (da) 2019-11-18
RS59583B1 (sr) 2019-12-31
KR102648293B1 (ko) 2024-03-15
JP2020182478A (ja) 2020-11-12
KR20220127345A (ko) 2022-09-19
BR112016027196A2 (pt) 2018-01-30
KR102440293B1 (ko) 2022-09-05
ES2754508T3 (es) 2020-04-17
LT3145946T (lt) 2019-11-25
IL283280B2 (en) 2023-08-01
KR20170010803A (ko) 2017-02-01
PT3145946T (pt) 2019-11-20
JP7509821B2 (ja) 2024-07-02
IL248827A0 (en) 2017-01-31
AU2015261905A1 (en) 2016-12-01
CN107001431B (zh) 2022-11-01
EP3145946A1 (en) 2017-03-29
HRP20192050T1 (hr) 2020-02-07
CY1122701T1 (el) 2021-03-12
IL283280A (en) 2021-07-29

Similar Documents

Publication Publication Date Title
JP7509821B2 (ja) 細菌に基づくタンパク質送達
EP3377634B1 (en) Bacteria-based protein delivery
CA3005380C (en) Bacteria-based protein delivery
HK1236208A1 (en) Bacteria-based protein delivery
HK1236208B (en) Bacteria-based protein delivery
HK1256138B (en) Bacteria-based protein delivery
EA041646B1 (ru) Доставка белков, осуществляемая на основе бактерий
BR112018009782B1 (pt) Cepas bacterianas recombinantes gram-negativas transformadas com um vetor e vetores

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination